BioSyent Inc. – TSX:RX.V

BioSyent stock price today

CAD 7.2
-4.39
-37.93%
Financial Health
0
1
2
3
4
5
6
7
8
9

BioSyent stock price monthly change

+16.00%
month

BioSyent stock price quarterly change

+16.00%
quarter

BioSyent stock price yearly change

+28.18%
year

BioSyent key metrics

Market Cap
103.43M
Enterprise value
122.96M
P/E
18.91
EV/Sales
3.56
EV/EBITDA
12.39
Price/Sales
3.90
Price/Book
3.59
PEG ratio
0.96
EPS
0.59
Revenue
32.84M
EBITDA
9.20M
Income
7.05M
Revenue Q/Q
19.29%
Revenue Y/Y
19.98%
Profit margin
20.6%
Oper. margin
23.93%
Gross margin
78.73%
EBIT margin
23.93%
EBITDA margin
28.04%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

BioSyent stock price history

BioSyent stock forecast

BioSyent financial statements

BioSyent Inc. (TSX:RX.V): Profit margin
Jun 2023 7.96M 1.48M 18.63%
Sep 2023 8.87M 2.35M 26.5%
Dec 2023 8.27M 1.45M 17.54%
Mar 2024 7.73M 1.76M 22.87%
BioSyent Inc. (TSX:RX.V): Analyst Estimates
2025 38.7M 6.81M 17.61%
2026 42.5M 7.78M 18.33%
  • Analysts Price target

  • Financials & Ratios estimates

1.55%
Yield TTM
BioSyent Inc. (TSX:RX.V): Payout ratio
Payout ratio 28.69%
BioSyent Inc. (TSX:RX.V): Dividend Yield
2019
2020
2021
2022 0.56%
2023 1.79%
BioSyent Inc. (TSX:RX.V): Debt to assets
Jun 2023 39512935 6.44M 16.31%
Sep 2023 41396711 6.84M 16.54%
Dec 2023 41528939 6.76M 16.3%
Mar 2024 39996434 5.44M 13.61%
BioSyent Inc. (TSX:RX.V): Cash Flow
Jun 2023 3.07M 1.82M -2.03M
Sep 2023 2.40M -976.08K -1.13M
Dec 2023 822.70K -1.06M -1.28M
Mar 2024 1.27M -39.20K -2.16M

BioSyent other data

  • What's the price of BioSyent stock today?

    One share of BioSyent stock can currently be purchased for approximately $7.2.

  • When is BioSyent's next earnings date?

    Unfortunately, BioSyent's (RX.V) next earnings date is currently unknown.

  • Does BioSyent pay dividends?

    Yes, BioSyent pays dividends and its trailing 12-month yield is 1.55% with 29% payout ratio. The last BioSyent stock dividend of undefined was paid on 4 Sep 2025.

  • How much money does BioSyent make?

    BioSyent has a market capitalization of 103.43M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 13.12% to 31.59M US dollars.

  • What is BioSyent's stock symbol?

    BioSyent Inc. is traded on the TSX under the ticker symbol "RX.V".

  • What is BioSyent's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry.

  • How do i buy shares of BioSyent?

    Shares of BioSyent can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • When BioSyent went public?

    BioSyent Inc. is publicly traded company for more then 29 years since IPO on 8 May 1996.

  • What is BioSyent's official website?

    The official website for BioSyent is biosyent.com.

  • Where are BioSyent's headquarters?

    BioSyent is headquartered at 2476 Argentia Road, Mississauga, ON.

  • How can i contact BioSyent?

    BioSyent's mailing address is 2476 Argentia Road, Mississauga, ON.

BioSyent company profile:

BioSyent Inc.

biosyent.com
Exchange:

TSX

Full time employees:

0

Industry:

Drug Manufacturers—Specialty & Generic

Sector:

Healthcare

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

2476 Argentia Road
Mississauga, ON L5N 6M1

:
ISIN: CA0906901081
: